Results 251 to 260 of about 75,992 (272)

Nivolumab

Reactions Weekly, 2018
  +5 more sources

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell, 2017
Nadeem Riaz, Jonathan J Havel, Vladimir Makarov   +2 more
exaly  

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Matthew D Hellmann, Margaret K Callahan, Emiliano Calvo   +2 more
exaly  

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

ESMO Open, 2018
Shin Hye Yoo, Bhumsuk Keam, Mišo Kim
exaly  

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2020
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel   +2 more
exaly  

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Journal of Thoracic Oncology, 2019
Neal Ready, Anna F Farago, Filippo de Braud   +2 more
exaly  

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Journal of Hepatology, 2020
Bruno Sangro, Ignacio Melero, Samir Wadhawan   +2 more
exaly  

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

European Journal of Cancer, 2019
Edwin A Basak, Daan P Hurkmans, Sander Bins   +2 more
exaly  

Ipilimumab/nivolumab/Nivolumab/Nivolumab/relatlimab

Reactions Weekly
openaire   +1 more source

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Lancet, The, 2017
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau   +2 more
exaly